We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+38.63%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$566M
AUM Growth
-$36.9M
Cap. Flow
-$112M
Cap. Flow %
-19.7%
Top 10 Hldgs %
52.22%
Holding
76
New
5
Increased
6
Reduced
14
Closed
25

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$20.6M
2
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.7M
3
ZLAB icon
Zai Lab
ZLAB
+$9.29M
4
OMER icon
Omeros
OMER
+$8.48M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$7.71M

Top Sells

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$23.5M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$22.9M
3
BPMC
Blueprint Medicines
BPMC
+$15.7M
4
BLUE
bluebird bio
BLUE
+$14.8M
5
NVRO
NEVRO CORP.
NVRO
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYOK
1
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$45.9M 8.11%
1,071,889
+71,889
+7% +$2.29M
RXDX
2
DELISTED
Ignyta, Inc.
RXDX
$43.2M 7.63%
3,500,000
+2,000,000
+133% +$20.6M
OMER icon
3
Omeros
OMER
$845M
$36.8M 6.49%
1,700,000
+400,000
+31% +$8.48M
ANAB icon
4
AnaptysBio
ANAB
$1.54B
$35M 6.17%
1,000,000
+200,531
+25% +$5.41M
TBPH icon
5
Theravance Biopharma
TBPH
$873M
$32.5M 5.74%
950,000
– –
PTLA
6
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$27M 4.77%
500,000
-400,000
-44% -$23.5M
GTHX
7
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$22.3M 3.94%
897,505
+417,519
+87% +$7.71M
BLUE
8
DELISTED
bluebird bio
BLUE
$18.9M 3.33%
10,615
-10,615
-50% -$14.8M
QTNT
9
DELISTED
Quotient Limited Ordinary Shares
QTNT
$17.2M 3.03%
87,148
-1,577
-2% -$315K
CLSD
10
DELISTED
Clearside Biomedical
CLSD
$17M 3%
129,392
– –
JUNO
11
DELISTED
Juno Therapeutics, Inc.
JUNO
$16.8M 2.97%
375,000
-375,000
-50% -$12.8M
OMER icon
12
CALL
Omeros
OMER
$845M
$16.2M 2.86%
+750,000
New +$15.9M
NBIX icon
13
Neurocrine Biosciences
NBIX
$18.2B
$15.3M 2.71%
250,000
– –
ACRS icon
14
Aclaris Therapeutics
ACRS
$715M
$14.2M 2.51%
550,000
-170,000
-24% -$4.56M
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$12.1M 2.13%
+388,574
New +$11.7M
EGRX
16
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$11.9M 2.11%
200,000
– –
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$11.7M 2.07%
+1,000,000
New +$5.79M
ARRY
18
DELISTED
Array Biopharma Inc
ARRY
$11.1M 1.95%
900,000
– –
ALDR
19
DELISTED
Alder Biopharmaceuticals
ALDR
$11M 1.95%
900,000
– –
HRTX icon
20
Heron Therapeutics
HRTX
$93.4M
$9.21M 1.63%
570,000
– –
NVRO
21
DELISTED
NEVRO CORP.
NVRO
$9.09M 1.6%
100,000
-170,000
-63% -$14.6M
BOLD
22
DELISTED
Audentes Therapeutics, Inc
BOLD
$9.06M 1.6%
323,545
– –
ZLAB icon
23
Zai Lab
ZLAB
$2.07B
$8.99M 1.59%
+333,166
New +$9.29M
PTGX icon
24
Protagonist Therapeutics
PTGX
$8.55B
$8.84M 1.56%
500,000
– –
KA
25
DELISTED
Kineta, Inc. Common Stock
KA
$7.99M 1.41%
27,172
– –
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q3 2017 Portfolio in Review

As of Q3 2017, Cormorant Asset Management held 76 positions worth $566M, down 6.1% from $603M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Cormorant Asset Management withdrew a net $112M in Q3 2017, closing 25 positions and reducing 14 holdings. Its most notable exit was Lakefront Biotherapeutics American Depositary Shares, an estimated $22.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 84% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock worth $12.1M.

  • Cormorant Asset Management's largest Q3 2017 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 388,574 shares worth $12.1M.
  • Cormorant Asset Management added most to Ignyta, Inc. in Q3 2017, an estimated $20.6M increase.
  • Cormorant Asset Management's biggest Q3 2017 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $23.5M.
  • Cormorant Asset Management fully exited Lakefront Biotherapeutics American Depositary Shares in Q3 2017, selling an estimated $22.9M.
  • Cormorant Asset Management's ten largest holdings make up 52% of its $566M portfolio in Q3 2017.
  • Cormorant Asset Management opened 5 new positions and closed 25 in Q3 2017.
  • Cormorant Asset Management's portfolio value fell 6.1% quarter-over-quarter to $566M.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.